Clinical Trials for Head And Neck Cancer

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors after standard treatment, or with no suitable standard option, receive intratumoral MQ710 alone or with pembrolizumab; combination cohorts focus on cutaneous squamous cell carcinoma, Merkel cell carcinoma, melanoma, and head and neck squamous cell carcinoma, generally after anti–PD-1 therapy. MQ710 is an engineered vaccinia-based virotherapy designed to enhance cGAS–STING signaling and antitumor T-cell activity; pembrolizumab blocks PD-1.

ClinicalTrials.gov ID: NCT05859074